Stock Analiz

NVS vs AZN stock comparison

Novartis vs. Astrazeneca · data as of November 13, 2026

Novartis (NVS) has a market value of about $306.3B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Novartis had revenue of $57.4B and Astrazeneca $62.4B.

On our five checks Astrazeneca scores higher: 2.8 out of 5 (average) against 2.0 (weak).

By area, the stronger company is Astrazeneca on value; Astrazeneca on future growth; Astrazeneca on shareholder returns.

Astrazeneca is cheaper on earnings (P/E 26.1 vs. 30.7).

Novartis leads on 7 of the compared lines and Astrazeneca on 16.

Side by side

NVSAZN
Size and price
Market cap$306.3B$286.0B
Share price$160.50$184.45
Score
Overall score (of 5)2.02.8
Value01
Future growth02
Track record44
Financial health33
Shareholder returns34
Valuation
P/E (TTM)30.726.1
Forward P/E17.016.5
Price / free cash flow21.946.9
Price / sales5.34.6
EV / EBITDA14.414.7
PEG2.021.20
DCF value vs. price−9%−38%
Business
Revenue$57.4B$62.4B
Net income$10.0B$11.0B
Free cash flow$14.0B$6.1B
Net margin17.5%17.7%
Gross margin (5-yr avg.)76.4%76.8%
ROIC (5-yr avg.)14.1%8.4%
Growth
Revenue growth (1 yr)8.4%8.6%
Revenue growth (5 yrs, per year)2.3%17.2%
EPS growth (5 yrs, per year)15.2%21.8%
Balance sheet and payouts
Net cash (cash minus debt)-$39.3B-$26.0B
Dividend yield2.95%1.74%
Shareholder yield6.0%1.9%
Analysts
Upside to average target−2%+13%
Consensus ratingHoldBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: NVS TTM to September 30, 2026, AZN TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Novartis or Astrazeneca?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Astrazeneca scores 2.8 out of 5 and Novartis 2.0; the table shows where each one is stronger.

Is Novartis cheaper than Astrazeneca?

On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Novartis at 30.7, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Novartis or Astrazeneca?

Over five years Astrazeneca grew revenue about 17.2% a year and Novartis about 2.3% a year.

Which pays a higher dividend?

Novartis yields 2.95% and Astrazeneca 1.74%.

Full Novartis analysis → Full Astrazeneca analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.